Evidence map›Paper›PMID 36975692›Full record

ArticleGels (Basel, Switzerland)2023

Biomanufacturing Recombinantly Expressed Cripto-1 Protein in Anchorage-Dependent Mammalian Cells Growing in Suspension Bioreactors within a Three-Dimensional Hydrogel Microcarrier.

Rachel Lev, Orit Bar-Am, Yoni Lati, Ombretta Guardiola, Gabriella Minchiotti, Dror Seliktar

Open access · goldFull text read
In one paragraph

Article in Gels (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Rachel LevFaculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Orit Bar-AmFaculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Yoni LatiFaculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 3200003, Israel.ORCID 0009-0006-8484-6020
Ombretta GuardiolaStem Cell Fate Laboratory, Institute of Genetics and Biophysics "A. Buzzati Traverso", CNR, 80131 Naples, Italy.
Gabriella MinchiottiStem Cell Fate Laboratory, Institute of Genetics and Biophysics "A. Buzzati Traverso", CNR, 80131 Naples, Italy.ORCID 0000-0003-0225-9043
Dror SeliktarFaculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Technion – Israel Institute of Technology · ILInstitute of Genetics and Biophysics · IT

Funding

H2020 ITN 210488358Israel Science Foundation 2130/19
6 · The paper itself

Abstract

Biotherapeutic soluble proteins that are recombinantly expressed in mammalian cells can pose a challenge when biomanufacturing in three-dimensional (3D) suspension culture systems. Herein, we tested a 3D hydrogel microcarrier for a suspension culture of HEK293 cells overexpressing recombinant Cripto-1 protein. Cripto-1 is an extracellular protein that is involved in developmental processes and has recently been reported to have therapeutic effects in alleviating muscle injury and diseases by regulating muscle regeneration through satellite cell progression toward the myogenic lineage. Cripto-overexpressing HEK293 cell lines were cultured in microcarriers made from poly (ethylene glycol)-fibrinogen (PF) hydrogels, which provided the 3D substrate for cell growth and protein production in stirred bioreactors. The PF microcarriers were designed with sufficient strength to resist hydrodynamic deterioration and biodegradation associated with suspension culture in stirred bioreactors for up to 21 days. The yield of purified Cripto-1 obtained using the 3D PF microcarriers was significantly higher than that obtained with a two-dimensional (2D) culture system. The bioactivity of the 3D-produced Cripto-1 was equivalent to commercially available Cripto-1 in terms of an ELISA binding assay, a muscle cell proliferation assay, and a myogenic differentiation assay. Taken together, these data indicate that 3D microcarriers made from PF can be combined with mammalian cell expression systems to improve the biomanufacturing of protein-based therapeutics for muscle injuries.

Indexed as

bioreactorHEK293 cellshydrogelmicrocarrierprotein therapeuticsrecombinant protein

Identifiers

PMID36975692
PMCPMC10048735
OpenAlexW4327950414

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read104
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.